NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
9 trialsNCT01639911 2019-07-22
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
Phase 1 Completed
NCT01503372 2019-02-12
PaFLO
Charite University, Berlin, Germany
Phase 2 Completed
NCT01438554 2018-08-29
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00540943 2017-11-29
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00370513 2017-11-17
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00387387 2017-11-17
Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)
GlaxoSmithKline
Phase 1 Completed
NCT01524848 2017-05-10
PAGIST
Scandinavian Sarcoma Group
Phase 2 Completed
NCT01130805 2016-04-15
A Study of Pazopanib With CAPEOX in AGC Patients
Samsung Medical Center
Phase 2 Completed